Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Nuedexta in Subjects With ALS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria~* Age 18 years or older~* Exhibits bulbar dysfunction manifested by dysarthria and/or dysphagia, according to PI judgment, exhibits a score of 55 or above on the CNS-Bulbar Function Scale~* Capable of providing informed consent and following trial procedures~* Geographic accessibility to the site~* Women must not be able to become pregnant for the duration of the study and must be willing to be on two contraceptive therapies~* Slow vital capacity (SVC) measure ≥50% of predicted for gender, height, and age at the screening visit~* Must be able to swallow capsules throughout the course of the study, according to PI judgment~* Subjects must not have taken riluzole for at least 30 days or be on a 50mg BID dose of riluzole for at least 30 days prior to randomization (subjects how have never taken riluzole are permitted in the study)~* Subjects taking anti-sialorrhea medication(s) must be on a stable dose for at least 30 days prior to randomization (anti-sialorrhea naïve subjects are permitted in the study)~* Must be able to safely swallow at least 30 milliliters (mLs) of water for the water swallowing test~Exclusion Criteria:~* Prior use of Nuedexta®~* Current use of dextromethorphan, quinidine, quinine, mefloquine or opioids~* History of quinidine, quinine, or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions~* History of known sensitivity or intolerability to dextromethorphan~* Use of an mono amine oxidase inhibitor (MAOI) or within 14 days of stopping an MAOI~* Prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, or heart failure~* Complete atrioventricular (AV) block without implanted pacemaker, or subjects at high risk of complete AV block~* Concomitant use with drugs that both prolong QT interval and are metabolized by cytochrome P 2D6 (CYP2D6) (i.e., thioridazine or pimozide)~* Exposure to any other experimental agent (off-label use or investigational) within 30 days prior to Baseline Visit~* Invasive ventilator dependence, such as tracheostomy~* Any history of either substance abuse within the past year, unstable psychiatric disease, cognitive impairment, or dementia, according to PI judgment~* Placement and/or usage of feeding tube~* Pregnant women or women currently breastfeeding~* Unable to turn diaphragm pacing device off during swallowing tests~* Salivatory Botox within 90 days (3 months) of screening~* Salivatory radiation within 180 days (6 months) of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nuedexta then Matching Placebo (Type: OTHER): Subjects in this arm will receive treatment with Nuedexta first for 28 days (±3 days) and then crossed over to receive treatment with matching placebo for 28 days (±3 days).
- Matching Placebo then Nuedexta (Type: OTHER): Subjects in this arm will receive treatment with matching placebo first for 28 days (±3 days) and then crossed over to receive treatment with Nuedexta for 28 days (±3 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete